Clinical trial
Riluzole in Huntington's Disease
NCT00277602 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00277602 |
|---|---|
| Title | Riluzole in Huntington's Disease |
| Official title | A Phase III Multicenter, Double-Blind, Parallel-Group, Placebo Controlled Study to Measure the Effect of Riluzole 50 mg b.i.d. Over a Period of Three Years on the Progression of Huntington's Disease |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Huntington Disease |
| Intervention type | Drug |
| Interventions | Riluzole |
| Enrollment | 537 |
| Start date | Nov 1, 1999 |
| Primary completion | Jul 1, 2004 |
| Completion | Jul 1, 2004 |
| First posted | Jan 16, 2006 |
| Last update posted | Feb 17, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: